Watch this brief video to get the exciting story or keep reading for 10 surprising reasons this company could bring you windfall profits:
This video reveals what you need to know about the company that could become a global leader in providing high-quality, low -cost medical cannabis. Watch it now or read below for all surprising reasons this stock could become such a big winner.
By James Dale Davidson, Editor
10 Reasons You Could Make Windfall Profits in the $57 Billion Medical Cannabis Boom
A disruptive under-the-radar company has taken the lead in low-priced medical cannabis production that could put it on the road to massive profits.
The company has a number of extraordinary competitive advantages that convinced me to take a closer look at what it has to offer investors.
And now that I’ve done my due diligence, analyzed the company, spoken with management and even visited medical cannabis farms, I’ve concluded that early investors in Isracann Biosciences Inc. (ISCNF) could profit handsomely.In fact, I believe Isracann Biosciences Inc. could produce potential growth of 740% or more, just like its South American counterpart PharmaCielo.
“Older Americans are flocking to medical ,arijuana”
– The New York Times
“Now is the right time to bet big on marijuana ... the industry is poised to be gigantic ”
“By 2020 the legal cannabis market will create more than a quarter of a million jobs. This is more than the expected jobs from manufacturing, utilities, or even government jobs.”
“The legal cannabis industry in the U.S. may grow to $50 billion in the next decade, expanding to more than eight times its current size.”
“Cannabis sales in U.S. growing faster than dot-com boom of 2000”
– International Business Times
“[Cannabis] is the No. 1 industry you need to be paying attention to ”
– Inc Magazine
Over the last few years, cannabis for medical use has begun to gain widespread acceptance in the medical community as a safe alternative to prescription painkillers, opioids, and other prescription drugs. And that’s simply because hundreds of medical studies have proven its effectiveness as a pain reliever and as a treatment for a variety of health problems.
Here’s just a few of the health issues that medical cannabis has been proven to help:
•Reduces arthritis pain, according to studies published in Rheumatology, PLoS ONE and The European Journal of Neuroscience.
•Relieves migraines, cluster headaches, and other headache disorders, according to large-scale review of literature by researchers at the Cleveland Clinic Neurological Institute.
•Reduces inflammation and oxidative stress — both of which are associated with chronic disease and chronic pain — according to research at both the U.S. National Institutes of Health and University of Massachusetts Medical School.
•Relieves sore muscles, according to recent research published in the journal The Neurologist. Research at the Mayo Clinic got similar results.
•Reduces debilitating neuropathy pain according to a study by the National Institutes of Health and an additional study commissioned by the U.S. Department of Veterans Affairs.
•Helps with diabetic nerve damage: Cannabidiol has been found to prevent nerve endings from deteriorating, and an Italian university study showed it was able to restore nerve function in the sciatic nerve of diabetic rats.
•Relief from epilepsy and seizures, according to research published in the journal Epilepsy and Behavior.
These studies are just a small sampling of the hundreds of clinical studies that prove the effectiveness of medical cannabis for a myriad of health concerns.
As the evidence piles up, the medical establishment’s view of medical cannabis has become more and more positive. This is perhaps best shown by the outspoken voice of Dr. Sanjay Gupta, M.D. — neurologist and CNN’s Chief Medical Correspondent.
For years, Dr. Gupta was skeptical of medical cannabis. However, he recently made a complete about-face, publicly stating that we have been “systematically misled” when it comes to medical cannabis.
In an April 24, 2018 letter to Attorney General Jeff Sessions, he wrote in part …
“I feel obligated to share the results of my five-year-long investigation into the medical benefits of the cannabis plant. Before I started this worldwide, in-depth investigation, I was not particularly impressed by the results of medical marijuana research, but a few years later, as I started to dedicate time with patients and scientists in various countries, I came to a different conclusion.
Not only can cannabis work for a variety of conditions such as epilepsy, multiple sclerosis, and pain … sometimes, it is the only thing that works.”
Dr. Gupta’s reference to pain is especially timely when you consider that America’s opioid crisis kills more than 47,000 citizens every year. As a result, many doctors now recommend medical cannabis instead of opioids for pain. And it seems to work.
Says Dr. Mehmet Oz, host of The Dr. Oz Show, “[Cannabis] may be the answer to America’s opioid crisis ... it absolutely should be widely available in America.”
U.S. sales of medical cannabis are expected to surpass $8 billion by 2024. The International Business Times reports that “legal cannabis sales in America are growing at a rate faster than the dot-com boom of 2000.”
Globally, medical cannabis is expected to reach $57.5 billion by 2026, according to Credence Research. When you consider that the global market was just $11 billion in 2017, that’s a lot of growth yet to come.
Let’s face it… you won’t find another multi billion-dollar market anywhere in the world growing at a 25% compound annual growth rate. At that pace, the market will DOUBLE in just three years … and take select medical cannabis stocks along for a very profitable ride.
All this growth is making a lot of companies — and their investors — rich beyond belief.
77 New Cannabis Millionaires
If you’ve been watching, you know that cannabis stocks have been among the best stock market performers, with 21 stocks handing investors returns of up to 1,000% since 2017.
Investors have been able to rake in impressive gains from the so-called “Big Four” medical cannabis stocks alone…
In fact, a leading Canadian business magazine recently reported that 77 ordinary investors — including a janitor — have become millionaires by investing in cannabis stocks.
However, the growth of the medical cannabis industry isn’t over by a long shot.
Savvy investors will continue to have the same opportunity by picking the right stocks with the best chance of handing out stellar returns.
We’re also seeing a wave of changing political sentiment that has led to the legalization of medical cannabis in 33 U.S. states.
It’s widely expected that the 17 states where it remains illegal will soon follow suit.
A growing number of foreign countries are also giving the green light to medical cannabis, helping to drive the red-hot growth of the market.
So far, 30 countries — including Australia, Germany, and Israel — have legalized cannabis for at least some uses. And at least a dozen other countries are gearing up to do the same.
They include France, Iceland, Spain, Portugal, the Netherlands, Peru, Colombia, Czech Republic, and Jamaica.
With medical cannabis quickly gaining momentum, the time to invest is now.
Isracann Biosciences Inc. (ISCNF) is a Canadian company that’s quickly positioning itself to dominate the medical cannabis market in Israel and throughout Europe.
The company is the first public company in Israel, listed in Canada, intending to focus solely on the production of low-cost, pharmaceutical-grade medical cannabis.
This is important because it would be difficult to overstate the enormous advantage of being a first-mover in a region that most people believe will be a medical cannabis capital going forward because of its leadership in cannabis research and ideal growing conditions.
Put simply, the first company to enter a new market typically dominates that market.
This advantage allows the company to establish strong brand recognition, distribution channels, and customer loyalty before competitors enter the arena. Plus, it allows for extra time to perfect its products.
Most often, the first-mover has established sufficient market share and a solid enough customer base that it maintains the majority of the market even after competitors move in to try and capitalize on the first-mover’s success.
Overall, it positions the company for steady demand, faster growth, and potentially higher profits.
Israel is a powerhouse of pharmaceutical research, particularly in medical cannabis.
It’s been the medical cannabis research capital of the world for more than 51 years — and is rich in cannabis technology and agricultural technology. In fact, no other country comes close to Israel’s superior medical cannabis research.
And Isracann Biosciences Inc. (ISCNF) has strategically positioned itself right in the middle of it all.
For example, the company has insider access to the newest, groundbreaking research coming out of Isreal, home to Dr. Raphael Mechoulam, the legendary organic chemist.
In the 1960s, Dr. Mechoulam was one of the first people to isolate, analyze, and synthesize tetrahydrocannabinol (THC) and was a leader in researching cannabidiol (CBD) — the two major compounds in the cannabis plant.
He was also the first to highlight the medical efficacy of CBD as an anti-psychotic and as a treatment for chronic pain and seizures.
He also discovered the human endocannabinoid system — the system in the body that directly interacts with medical cannabis, and is responsible for its wide range of benefits. He has since developed a number of revolutionary cannabis-related treatments.
Dr. Mechoulam is now Professor of Medicinal Chemistry at Hebrew University, and is widely known as the world’s foremost cannabis researcher.
Hebrew University is a critical pipeline for medical cannabis research, and has played a crucial role in establishing medical cannabis worldwide.
Isracann Biosciences’ proximity to the research, scientific, and medical community in Israel — gives it a distinct advantage over any other medical cannabis grower anywhere in the world.
Israel is world-renowned as an agricultural innovation hub.
Much of this is due to its superb growing conditions. In fact, it enjoys climatic conditions that are just about perfect for growing high-quality, medical cannabis, including …
•Ideal Humidity — Safeguards plants from insects and enables optimal growth …
•Optimal Temperature — Reduces energy consumption in both winter and summer, saving considerable production costs …
•High-UV Sunlight — Approximately 300 days of high-UV sun annually (vital for effective growth of medical cannabis and high yields) leads to a further reduction in production costs …
•Multiple Growing Cycles — Translates to a higher yield per square foot over other countries.
In addition, Isracann Biosciences Inc. (ISCNF) uses state-of-the-art “closed greenhouses” that are fitted with micro-fiber cloth, a double set of doors, and other features to help keep pests and bacteria away from the plants.
The greenhouses also use a reverse vacuum system. So in the event of a breach, they can quickly suck out the air inside the greenhouse, and recirculate it with clean air. As a result, there is far less wastage due to pests and other environmental factors.
Isracann Biosciences Inc. holds the rights to more than 250,000 square feet of prime agricultural land, with preliminary production licenses.
That's an area roughly equivalent to the size of four football fields.
Initially, the company is building a 232,900-square-foot facility that has the potential to produce about 23,500 kg of medical cannabis annually. That would make it a leading medical cannabis grower in Israel.
That leads us to one of the biggest reasons why I believe Isracann Biosciences Inc. could help you build a fortune from the trend toward the global legalization of medical cannabis.
Altogether, Isracann’s advantages are such that its cost of production is expected to average as low as $0.30 per gram.
That’s less than half the cost of growing in a colder climate, such as Canada or Europe
To give you a little perspective … three of Canada’s largest medical cannabis producers — HEXO Corp. (formerly Hydropthecary Corp.), Aphria, and Aurora Cannabis — have a cost per gram of $0.74, $1.16, and $0.73 respectively.
All in all, that means Isracann Biosciences Inc. (ISCNF) would be able to grow the highest-grade medical cannabis at a much lower cost than its competitors.
That could give it a huge advantage as it rushes to meet the growing demand of a massively underserved domestic and international market.
Israel has the highest percentage of medical cannabis users in the world, and more than 10,000 medical cannabis patients on a wait-list right now due to a lack of legal supply.
The number of Israeli patients alone is estimated to exceed 50,000 in 2020.
Meanwhile, the medical cannabis market in the European Union is projected to hit $64 billion by 2028. Europe has a population of more than 741 million — more than twice that of the U.S. and Canada, which are the two largest medical cannabis markets today.
Germany alone reports that 10% of its population — or roughly 800,000 people — will be using medical cannabis.
Since legalizing medical cannabis in March 2017, Germany has faced a growing supply shortage due to the lack of companies experienced enough to meet the government’s stringent guidelines for a medical cannabis cultivation license.
Israel’s proximity gives Isracann Biosciences a giant advantage in accessing this massive, underserved European consumer base.
The average sale price of medical cannabis in Germany is between $15 and $22 per gram.
So with Isracann Biosciences’ intended ability to produce high-grade medical cannabis for as low as 30 cents per gram — plus significant cost saving advantages available in terms of transport and delivery — the profit potential is exponential.
Put simply, no other producer would be able to compete in this region with what Isracann Biosciences Inc. (ISCNF) plans to do in terms of producing high-grade medical cannabis at such low cost.
So the obvious question now is: Why hasn’t Isracann already taken Europe by storm?And that leads us to a key reason why now may prove to be the most opportune time ever to invest in Isracann Biosciences Inc. (ISCNF).
The chief bottleneck to entering European markets so far has been an Israeli law making it illegal to export medical cannabis.
However, last year the Israeli government recently unanimously approved a long-awaited law allowing for the export of medical cannabis and is implementing regulations for the licensing of medical cannabis businesses.
This effectively throws off the bow lines on the export of Israeli-grown medical cannabis to the booming worldwide legal market. In fact, Israel is projected to rack up over $1 billion in export sales over the next five years.
As Forbes reports, “Among the countries reportedly eager to trade with Israel include Australia, Germany, Austria, and Mexico.”
The effect of this new law on Isracann Biosciences Inc. over the coming months could be like throwing rocket fuel on a bonfire!
Billionaire investors are playing a big part in the growth of medical cannabis. For example:
•Privateer Holdings Inc. — a Seattle-based fund started nine years ago to focus on the cannabis industry — now owns a roughly 80% stake in Canadian medical cannabis producer Tilray Inc.
Privateer is backed by billionaire PayPal co-founder Peter Thiel.
•Chewing gum billionaire William Wrigley Jr. II became the CEO of Atlanta-based medical marijuana company Parallel (formerly Surterra Wellness). He made an initial investment in the company and led a $65 million funding round for the firm.
Parallel operates a number of medical marijuana and CBD dispensaries and grow facilities in Florida and Texas.
The Explosive Demand for Medical Cannabis — and Changing Laws –Make Isracann Biosciences Inc. (ISCNF) a Powerful Play!
For all these reasons and more, I believe this is a once-in-a-generation megatrend opportunity in medical cannabis. And it could put you in the front row seat to enjoy windfall gains.
What You Should Consider Now
JAMES DALE DAVIDSON
The man behind these startlingly accurate forecasts and remarkably profitable investment recommendations
James Dale Davidson is the editor of Strategic Investment and the founder of the National Taxpayer’s Union. He’s been forecasting the twists and turns of the economy and markets for more than 35 years now — making profitable investment recommendations every step of the way.
James is also the author or co-author of numerous investment bestsellers, including Blood in the Streets: Investment Profits in a World Gone Mad, The Great Reckoning: Protecting Yourself in the Coming Depression, The Sovereign Individual: Mastering the Transition to the Information Age, The Age of Deception and The Breaking Point: Profit from the Coming Money Cataclysm.
He’s known for predicting the death of the Soviet Union … the fall of the Berlin Wall … the rise of Islamic terrorism … and the bank bailouts.
Here are just a few examples of the kind of profit opportunities James routinely shares with his subscribers:
⮚ He predicted Donald Trump’s victory four months before the election and, with that in mind, made a surprising currency recommendation. Soon after the election, investors who followed James’ advice could have locked in profits of up to 4,100%.
⮚ Scythian Biosciences, a company developing a cannabinoid-based drug treatment for concussion, soared 860% after James’ recommendation.
⮚ In November 2017, with cryptocurrencies making headlines, he saw a fast profit opportunity with RIOT Blockchain. Within a month, it soared from $8.06 to $40.75, for a 405.5% gain.
James’ subscribers’ profit from his 35 years of experience and his history of accurate predictions … big-picture foresight … and geopolitical connections.
IMPORTANT NOTICE AND DISCLAIMER: All investments are subject to risk, which must be considered on an individual basis before making any investment decision. Strategic Investment is the publisher of these materials and is not responsible for errors and omissions. This publication is intended solely for information and educational purposes and is not to be construed, under any circumstances, as an offer to buy or sell, or a solicitation to buy or sell or trade, or as a personal recommendation to buy or sell or trade in any securities or commodities named in these materials. These materials are a paid advertisement. Information gathered to create these materials is from sources believed to be reliable, but is in no way guaranteed. Furthermore, you cannot be assured that you will profit or that any losses can or will be limited. It is important to know that no guarantee of any kind is implied or possible where projections of future conditions in the markets are attempted. Hypothetical or simulated performance results have certain inherent limitations as to liquidity and execution, among other variables. All readers should consult their own personal investment adviser before making an investment decision. Investing in securities is highly speculative and carries a great deal of risk, especially as to newer companies with comparatively short operating histories and limited earnings. This report contains projections regarding future operating results, which are forward-looking statements. Those projections were derived from sources that have not been verified independently. All forward-looking statements are believed to have a reasonable basis, but are subject to risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Those projections should not be considered a comprehensive representation of the featured company’s future performance. Strategic Investment is a paid circulation newsletter and is not a financial analyst, investment advisor or broker/dealer. These materials are a solicitation for subscriptions for the newsletter and a paid promotional advertisement of Isracann Biosciences Inc. (OTC: ISCNF). Strategic Investment expects to generate new subscriber revenue as a result of this advertisement. This paid advertisement includes a stock profile of Isracann Biosciences Inc. (ISCNF). Strategic Investment is an investment newsletter being advertised herein. This paid advertisement is intended solely for information and educational purposes and is not to be construed under any circumstances as an offer to buy or sell, or as a solicitation to buy or sell, any securities. Strategic Investment assumes no obligation to provide any future views in support of the highlighted company. In an effort to enhance public awareness of ISCNF and its securities, Isracann Biosciences Inc. (Payor) provided advertising agencies with a total budget of approximately two million fifty-seven thousand one hundred seventy-four dollars to cover the costs associated with creating, printing and distribution of this advertisement and other elements of this campaign in an effort to build investor awareness. Payor has represented to advertising agencies in writing that Payor has conducted a reasonable investigation or obtained appropriate written representations from ISCNF that it is the source of all funds that have been or will be paid to advertising agencies for this advertising campaign. Strategic Investment was paid thirty thousand dollars as a research fee. In addition, Strategic Investment may generate new subscription revenue, the amount of which is unknown at this time, as a result of the distribution of these materials. The advertising agencies involved in this campaign relied on information provided by Isracann Biosciences Inc. The advertising agencies will retain as their compensation any excess sums after all expenses are paid. As of the date these materials are first disseminated, neither Strategic Investment, the advertising agencies, nor any of their respective officers, principals or affiliates (as defined in the Securities Act of 1933, as amended, and Rule 501(b) promulgated thereunder) own or beneficially own any securities of Isracann Biosciences Inc., and will not purchase, receive or otherwise acquire any securities of Isracann Biosciences Inc. for a period of 90 days following the date this advertising campaign is concluded. The Payor has represented in writing to Strategic Investment and the advertising agencies that (1) its officers, directors, and principals (as defined in the Securities Act of 1933, as amended, and Rule 501(b) promulgated thereunder) are beneficial owners of the Company; (2) the Issuer and its officers, directors, and principals will not sell or otherwise disposed of any securities for a period of ninety (90) days following the conclusion of the Campaign; (3) neither Issuer and its officers, directors, and principals will purchase, receive or otherwise acquire any additional securities of the Company for a period of ninety (90) days following the conclusion of the Campaign; (4) Payor has implemented appropriate procedures to ensure the implementation of the foregoing representations and warranties to Strategic Investment and the advertising agencies. If successful, this advertisement will increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of ISCNF, increased trading volume, and possibly an increased share price of ISCNF’s securities, which may be temporary. This advertisement, the advertising agencies and Strategic Investment do not purport to provide a complete analysis of ISCNF’s financial position, operations or prospects, and this is not to be construed as a recommendation by Strategic Investment. as an offer to buy or sell any security or as investment advice. An offer to buy or sell can only be made with accompanying disclosure documents and only in states and provinces for which they are approved. They are not, and do not purport to be, broker-dealers or registered investment advisors. This advertisement is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent publicly- available information about ISCNF and its industry. Further, readers are specifically urged to read and carefully consider the Risk Factors identified and discussed in ISCNF’s SEC filings. Investing in securities, particularly microcap securities such as ISCNF, is inherently speculative and carries a high degree of risk. Past performance does not guarantee future results. This advertisement is based exclusively on information generally available to the public and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the advertising agencies and Strategic Investment cannot guarantee the accuracy or completeness of the information The advertising agencies and Strategic Investment note that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect ISCNF’s actual results of operations. Factors that could cause actual results to differ include the size and growth of the market for ISCNF’s products and/or services, the company’s ability to fund its capital requirements in the near term and long term, pricing pressures, etc. Strategic Investment is the publisher’s trademark. All trademarks used in this advertisement other than Strategic Investment are the property of their respective trademark holders and no endorsement by such owners of the contents of this advertisement is made or implied. The advertising agencies and Strategic Investment are not affiliated, connected, or associated with, and are not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made to any rights in any third-party trademarks. More information can be found on the Isracann Biosciences Inc. website (https://Isracann.com/). As with any low-priced stock, investors should use only risk capital they are willing to lose or hold for long-term investing.